Department of Health and Human Services December 2, 2005 – Federal Register Recent Federal Regulation Documents
Results 1 - 5 of 5
Request for Public Comment; Public Meetings in Calendar Years 2005 and 2006; Economic Impact of Federal Health Care Regulations
This notice announces the dates and locations of the Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation (ASPE) Town Hall meetings to be held in calendar years 2005 and 2006 to solicit public comment on quantifying the economic impact of major Federal regulations governing the health care industry. These public meetings provide a forum for interested parties to make oral presentations and/or to submit written comments about the impact of regulations. In particular, commenters are requested to provide an estimate of the economic impact of Federal health care regulations, guidance documents, or paperwork requirements, and also to describe the methods used to calculate the economic impact of the regulations. The Town Hall meetings will be held in several cities across the country to provide an opportunity for input. In addition, individuals may also submit written comments for consideration regardless of their ability to attend the Town Hall meetings.
Revocation of Status of Specific Products; Group A Streptococcus
The Food and Drug Administration (FDA) is removing the regulation applicable to the status of specific products; Group A streptococcus. FDA is removing the regulation because the existing requirement for Group A streptococcus organisms and derivatives is both obsolete and a perceived impediment to the development of Group A streptococcus vaccines. The regulation was written to apply to a group of products that are no longer on the market. We are taking this action as part of our continuing effort to reduce the burden of unnecessary regulations on industry and to revise outdated regulations without diminishing public health protection. We are issuing the removal directly as a final rule because it is noncontroversial, and there is little likelihood that we will receive any significant adverse comments. Elsewhere in this issue of the Federal Register, we are publishing a companion proposed rule under our usual procedures for notice and comment in the event that we receive any significant adverse comments on the direct final rule. If we receive any significant adverse comments that warrant terminating the direct final rule, we will consider such comments on the proposed rule in developing the final rule.
Revocation of Status of Specific Products; Group A Streptococcus; Companion Document to Direct Final Rule
The Food and Drug Administration (FDA) is proposing to remove the regulation applicable to the status of specific products; Group A streptococcus. FDA is proposing to remove the regulation because the existing requirement for Group A streptococcus organisms and derivatives is both obsolete and a perceived impediment to the development of Group A streptococcus vaccines. The regulation was written to apply to a group of products that are no longer on the market. We are taking this action as part of our continuing effort to reduce the burden of unnecessary regulations on industry and to revise outdated regulations without diminishing public health protection. This proposed rule is a companion to the direct final rule published elsewhere in this issue of the Federal Register. We are taking this action because the proposed change is noncontroversial, and we do not anticipate any significant adverse comments. If we receive any significant adverse comments that warrant terminating the direct final rule, we will consider such comments on the proposed rule in developing the final rule.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.